Skip to main content

Nana Liu

Associate

[email protected]

+1.617.348.1703

Share:

Nana focuses her practice on patent litigation, and handles cases at the International Trade Commission, in federal district courts, and in the US Court of Appeals for the Federal Circuit. She has litigated matters involving high tech, biologic, and chemical innovations, including Hatch-Waxman cases. 

Nana serves as a key member of case teams at all stages of litigation, including as primary technical associate. In this capacity, she collaborates in the day-to-day with expert witnesses, and is involved in the development of infringement/non-infringement and validity/invalidity theories.  She also handles domestic industry economic analysis in Section 337 cases.  She routinely has a lead role in pre-suit diligence, fact and expert discovery, claim construction, preparing fact witnesses and expert witnesses for deposition, motion practice, trial preparation, and post-trial briefing. 

Prior to joining Mintz, Nana served as a judicial law clerk to the now-retired Hon. Andrew R. Grainger of the Massachusetts Appeals Court.

While earning her law degree, Nana served as a judicial intern to the Hon. Norman H. Stahl, a Senior Judge of the US Court of Appeals for the First Circuit, and was a legal intern with Greater Boston Legal Services’ Asian Outreach Unit. In law school, Nana was a senior staff editor of the Northeastern University Law Journal.

Prior to law school, Nana spent several years conducting bacterial immunology R&D at the Cambridge, Massachusetts location of a global company that specializes in the development of new vaccines.

Education

  • Northeastern University (JD)
  • Wellesley College (BA, Biological Chemistry)

Experience

  • Certain Video Processing Devices, Components Thereof, and Digital Smart Televisions Containing the Same (337-TA-1222) – Representing DivX, a video codec company headquartered in San Diego, in enforcing patents before the ITC, in the District of Delaware and Eastern District of Texas, and in German and Brazilian courts. The asserted patents involve innovations relating to internet video and streaming media. LG and Samsung settled prior to the ITC evidentiary hearing which was held with remaining respondents in July 2021.
  • Certain Semiconductor Devices, Products Containing the Same, and Components Thereof (II) (337-TA-1177) - Represented GlobalFoundries at the International Trade Commission and in multiple Western District of Texas actions, involving the direct and indirect infringement of four patents related to semiconductor devices, integrated circuits, and products containing the same. Additional defendants in these actions included Apple, Broadcom, Cisco, nVidia, Arista, Asus, and Lenovo. Within 2.5 months of filing at the ITC, the cases settled on favorable terms.
  • Certain Semiconductor Devices, Integrated Circuits, and Consumer Products Containing the Same (337-TA-1149) – Mintz represented Innovative Foundry Technologies as part of a global enforcement strategy to protect 5 asserted patents relating to semiconductor fabrication and packaging. Respondents for the ITC matter included Taiwan Semiconductor Manufacturing Company, Qualcomm Incorporated, MediaTek, and Vizio. Cases were simultaneously filed in U.S. District Court and internationally in Germany and China. The investigation was instituted in March of 2019 and resolved favorably prior to the conclusion of discovery in August of 2019.
  • Certain Human Milk Oligosaccharides and Methods of Producing the Same (337-TA-1120) – Represented Glycosyn LLC as complainant before the ITC against respondent Jennewein Biotechnologies GmbH, a large global competitor. The complaint alleged unlawful and unauthorized importation and production and/or manufacture of 2'-fucosyllactose oligosaccharides that directly infringe one or more claims of Glycosyn's U.S. Patent No. 9,453,230. Following oral hearing in May 2019, the Administrative Law Judge issued an Initial Determination finding that Jennewein had infringed claims of Glycosyn’s patent and recommended that a limited exclusion order issue, including a certification provision with heightened requirement.
  • Kowa Company, Ltd., et al v. Amneal Pharmaceuticals, LLC, 2018-1051 (Fed. Cir.) – Successfully represented appellees Kowa Company, Kowa Pharmaceuticals America, Inc. and Nissan Chemical Corporation at the Court of Appeals for the Federal Circuit, against Amneal Pharmaceuticals. The Federal Circuit affirmed the judgment of the U.S. District Court for the Southern District of New York (Crotty, J.), upholding the validity and infringement of two patents owned by our clients. Oral argument took place on Thursday, December 6, 2018, and the Court issued its judgment early Monday morning, December 10.

Involvement

  • Volunteer, Civil Appeals Clinic, Volunteer Lawyers Project of the Boston Bar Association
  • Volunteer, New England Legal Foundation
  • Mentor, Minds Matter Boston

Languages

- Mandarin

Recent Insights

News & Press

Viewpoints

Intellectual Property Viewpoints Thumbnail

PTAB statistics show interesting trends for Orange Book and biologic patents in AIA proceedings

August 24, 2021 | Blog | By Peter Cuomo, Joe Rutkowski, Nana Liu

The PTAB recently published the first update to its 2019 study of AIA trials involving petitions challenging Orange Book-listed patents and biologic patents through June 2021. Highlights of these pharmaceutical patent challenge statistics include, e.g., the number of these petitions filed, the number of instituted trials, and the trial outcomes since fiscal year 2013.
Read more
Intellectual Property Viewpoints Thumbnail
See the guidelines on the procedural aspects of filing a motion to amend claims.
Read more
IPRs and Other Post-Grant Porceedings Viewpoint Thumbnail
In inter partes review (IPR) proceedings, the PTAB will often uphold the validity of dependent claims despite finding the independent claim invalid.  Dependent claims recite additional limitations that must be separately accounted for in the prior art references in the Petitioner’s asserted grounds.
Read more
IPRs and Other Post-Grant Porceedings Viewpoint Thumbnail
Discovery procedures in inter partes review (“IPR”) proceedings, governed by 37 CFR § 42.51, are more limited in scope and timing compared to cases in district court. 
Read more
IPRs and Other Post-Grant Porceedings Viewpoint Thumbnail
The expert declaration provides a unique opportunity for Patent Owners to bolster their case during the discovery period of an inter partes review (“IPR”) proceeding. We previously detailed how to effectively use an expert declaration in the Patent Owner’s Preliminary Response (“POPR”). Now we turn to maximizing your expert’s testimony for the Patent Owner’s Response (“POR”).
Read more
IPRs and Other Post-Grant Porceedings Viewpoint Thumbnail

PTAB Reinforces Uneven Evidentiary Playing Field in IPRs

April 16, 2021 | Blog | By Daniel Weinger, Nana Liu

The U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) recently grappled with the admission into evidence of expert deposition testimony that was presumably harmful to the petitioner in an inter partes review (IPR), and barred the testimony from coming into evidence. 
Read more
Federal Circuit Appeals Viewpoint Thumbnail

In Hatch-Waxman litigation, Federal Circuit restricts venue under the TC Heartland to districts relating to ANDA filings

November 12, 2020 | Blog | By Adam Samansky, Peter Cuomo, Joe Rutkowski, Nana Liu

On November 5, 2020, the United States Court of Appeals for the Federal Circuit, in Valeant Pharmaceuticals N. Am. LLC v. Mylan Pharmaceuticals Inc., No. 19-2402, resolved a split among district courts over what constitutes “acts of infringement” sufficient to support venue in the context of a Hatch-Waxman litigation.  
Read more
Intellectual Property Viewpoints Thumbnail

Federal Circuit Upholds Application of Dedication-Disclosure Doctrine at the Pleading Stage

May 15, 2020 | Blog | By Thomas Wintner, Adam Samansky, Nana Liu

On May 8, 2020, the Court of Appeals for the Federal Circuit affirmed the District of Delaware’s application of the disclosure-dedication doctrine in granting a motion for judgment on the pleadings in Eagle Pharmaceuticals Inc. v. Slayback Pharma LLC, No. 19-1924. 
Read more
Intellectual Property Viewpoints Thumbnail
Mintz is recognized as among the top ten firms in ITC Section 337 litigation by Patexia in its inaugural "ITC Intelligence Report". We are pleased to be among the firms included in this publication and thrilled that it has come on the heels of a great year at the ITC for the Mintz team.
Read more
Viewpoint Thumbnail

Federal Circuit affirms Safe Harbor ruling and $70 million award in Amgen Inc. v. Hospira, Inc.

December 20, 2019 | Blog | By Thomas Wintner, Peter Cuomo, Nana Liu

On December 16, 2019, the Court of Appeals for the Federal Circuit issued an opinion that fully upheld the District of Delaware’s denial of Hospira, Inc.’s motion for judgment as a matter of law (JMOL), or alternative motion for new trial, in Amgen Inc. v. Hospira, Inc., Nos. 2019-1067, 2019-1102.  
Read more

News & Press

News Thumbnail
Law360 reported that Mintz client American video codec company DivX, an early innovator in the digital streaming video and digital rights management scene, has reached confidential settlements with LG and Samsung, resolving international litigation claiming they infringe DivX’s streaming patents with their smart televisions. The Mintz team representing DivX is led by Member and Chair of the firm’s Intellectual Property Division Michael Renaud and Member Adam Rizk and includes Member and Chair of the firm’s Intellectual Property Litigation Practice Matthew Hurley, Members Keith Carroll, Marguerite McConihe, Michael McNamara, Samuel Davenport, and Daniel Weinger, and Associates Matthew Karambelas, Jessica Perry, and Nana Liu.